Suspension of human monocomponent insulin manufactured by recombinant DNA technology (genetic engineering). containing 30% amorphous insulin and 70% crystalline insulin with a protracted effect. Onset of action: 2½ hours; peak activity: 7-15 hours; duration of action: up to 24 hours.
This is an abbreviated drug entry for INSULIN MONOTARD HM (ge)
To see the full monograph for INSULIN MONOTARD HM (ge)